Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab steroid-sparing study in severe refractory asthma
2012-001497-29Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Mepolizumab adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percent reduction of oral corticosteroid dose at week 24. Started Jul 2012; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2012-001497-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001497-29.